A denial letter is an opening bid. Plans deny GLP-1 requests by default because most people never appeal — and reversal rates for well-documented appeals are meaningfully high across the insurance literature. This file turns the coverage file’s map into the actual letter.
First, decode the denial
The letter names its reason, and the reason picks your strategy. “Not a covered benefit” (plan excludes weight-management drugs) is the hardest lane — you’re arguing for an exception or pivoting to a covered indication. “Not medically necessary” is the most winnable — it’s an evidence fight, and evidence is assemblable. “Step therapy not satisfied” means documenting prior attempts or their contraindications. “Prior authorization missing/incomplete” is administrative — often fixed by resubmission with the gaps filled. Match the counter to the code before writing a word.
The evidence stack, assembled
Winning appeals share a skeleton of exhibits: current BMI with date and a weight history showing chronicity; the comorbidity documentation that moves thresholds — hypertension, dyslipidemia, sleep-study results, prediabetes labs, or the cardiovascular history that engages Wegovy’s post-SELECT indication; a record of prior structured attempts (programs, dietitian visits, previous medications with outcomes or intolerances); the prescriber’s statement tying diagnosis to the specific label requested — the diagnosis-label match from our brand-mechanics files is the whole game here; and citations to the label itself plus major-society guidance recognizing pharmacotherapy for obesity. Screenshots of plan documents help when the plan’s own criteria support you — quote their policy back to them by page.
The letter, section by section
Keep it to two pages in this order. Header: member ID, claim/denial reference, drug and dose requested, prescriber contact. Ask: one sentence — “I am appealing the denial dated X and requesting coverage of Y as prescribed.” Clinical case: a paragraph of diagnosis, BMI, comorbidities, and history — facts with dates, no adjectives. Label match: a paragraph stating the FDA indication verbatim and mapping your chart to each criterion. Prior attempts: the step-therapy paragraph — what was tried, when, and why it failed or was inappropriate. Evidence: two or three sentences citing the pivotal-trial results and any society guidance, with the exhibits listed. Close: request a written response within the plan’s stated window and name your intent to pursue external review if denied. Signature, enclosures list, done. Adjectives lose appeals; dated facts win them.
Template skeleton to adapt
“I am writing to appeal the denial referenced above for [drug] prescribed by [prescriber] on [date]. I meet the FDA-labeled indication: [quote criterion], as documented by [exhibit]. My history includes [comorbidities with dates] and prior structured attempts including [program/medication, dates, outcome]. The requested therapy is supported by [trial result in one clause] and consistent with [plan’s own policy section, if favorable]. I request reversal of this denial and coverage as prescribed, and a written determination within [X] days per my plan documents. If this appeal is denied, I intend to pursue independent external review.” Fill brackets from your chart; delete anything you can’t document.
Levels, deadlines, and the external-review lever
Plans run one or two internal appeal levels with strict filing windows — the denial letter states yours; calendar it the day the letter arrives. Exhausting internal appeals unlocks the underused weapon: independent external review, where a reviewer outside the plan applies the evidence, and where documented, label-matched cases perform strongly. Urgent-review lanes exist when delay threatens health — your prescriber’s attestation triggers them. Employer plans add another door: HR benefits teams can request exceptions insurers won’t volunteer, and self-funded plans can simply decide to cover you.
What not to do
Don’t argue fairness, cost, or celebrity anecdotes — reviewers score criteria. Don’t let the prescriber’s office “handle it” without confirming anything was filed; ask for the confirmation number. Don’t miss the window while gathering perfect exhibits — file with what you have and supplement. And don’t misstate the chart: one inaccuracy discredits the true ninety percent.
The bottom line
Read the code, build the dated stack, mirror the label, cite their own policy, and escalate on schedule — through external review if needed. The process is tedious by design; tedium is a cost most appellants won’t pay, which is precisely why paying it works.
Two denials, two different letters
“Not medically necessary,” BMI 31 with sleep apnea. Her winning letter led with the sleep study — AHI 22, symptomatic — mapped to Zepbound’s OSA-adjacent evidence and her plan’s own BMI-plus-comorbidity criterion, quoted by section number. Reversed at first internal level in eleven days. “Not a covered benefit,” employer plan excluding weight drugs. His letter couldn’t beat an exclusion on criteria, so it did two other things: requested a formulary exception citing his cardiac history under the SELECT-era indication, and cc’d HR with a one-paragraph business case. The insurer held; HR’s benefits committee added coverage at plan renewal. Different codes, different levers — same discipline of dated facts aimed at the actual decision-maker.
Mini-FAQ
Should the appeal come from me or my prescriber? Both lanes exist; the strongest files pair a prescriber’s clinical letter with your member appeal — they’re read together. How long does it take? Internal levels typically resolve in weeks per plan-stated windows; urgent lanes compress to days with clinical attestation. Does compounded use help my case? No — plans adjudicate the labeled product; frame history with compounded product simply as prior therapy experience. Is it worth appealing a small copay difference? Usually not; save the machinery for denials of coverage itself. Where does this fail? True benefit exclusions on fully-insured plans — which is why the pivot to a covered indication, when your chart honestly supports one, is the single highest-yield move in this entire file.
The prescriber letter, engineered
The strongest exhibit is the clinical letter — and busy offices write better ones when you make it easy. Bring a one-page brief to the visit: the denial code verbatim, the label criterion to mirror, your dated history bulleted, and the exhibit list already assembled. Ask specifically for a letter that states the diagnosis with its code, maps each label criterion to chart evidence, documents step-therapy history or its contraindications, and closes with the medical-necessity sentence in the plan’s own vocabulary. Then ask the office to request a peer-to-peer review if the appeal stalls — a prescriber-to-plan-physician call that resolves a surprising share of contested cases, and that most patients never know to request. Offices run on templates; hand them a good one and you’ll get it back on letterhead.
Run it like a case file
Winning appellants keep a log: every call’s date, representative name, and reference number; every submission’s confirmation — portal receipt, fax confirmation, or certified-mail tracking; every deadline back-planned with a week’s margin. Submit through a channel that generates proof, keep copies of everything including the envelopes, and follow up in writing after any phone commitment (“Confirming our call today in which…”). If the clinical situation can’t wait the standard window — worsening comorbidity, a closing surgical timeline — have the prescriber invoke the expedited lane explicitly, in writing, with the clinical reason. None of this is dramatic; all of it converts “they lost my appeal” from a dead end into a documented violation of their own procedures — which external reviewers and state regulators read exactly the way you’d hope.
The last resorts — and staying treated meanwhile
Two escalations sit past external review. Your state insurance regulator takes consumer complaints, and a documented procedural failure — blown deadlines, ignored submissions — is exactly what those offices exist to chase; the case log you kept becomes the complaint, nearly verbatim. Self-funded employer plans are the asterisk: they answer to federal rather than state machinery, appeal rights still exist but route differently, and the HR-benefits lane from earlier grows correspondingly more important — your summary plan description names which world you’re in. Meanwhile, appeals take weeks, and lapsing therapy to wait is the one unforced error: bridge deliberately — the manufacturer self-pay channels and the verified flat rates in the ledger exist precisely for coverage gaps — and keep the treatment record unbroken, which itself strengthens the file. An appeal is a parallel process, not a pause button.
Last word: file even when the odds look poor. Appeals cost an evening and a stamp; the alternative costs list price monthly. Plans count on attrition — the entire economics of default denial assumes you’ll absorb the first no — and every well-documented appeal, win or lose, is also the paper trail that external reviewers, regulators, and next year’s formulary committee actually read. The no you accept silently is the only one that’s permanent.
Sources
Plan appeal procedures and external-review rights per your policy documents and state insurance regulators; FDA labels for indication language; pivotal-trial citations via the trials file. Primary links at sources.